The plant Cannabis sativa L. is the primary source of naturally occurring cannabidiol (CBD). When these plants contain more than 0.3% tetrahydrocannabinol (THC) by weight, they are generally referred to as marijuana plants. But, when the amount of THC does not exceed 0.3%, these plants are legally classified as industrial hemp.
Cannabidiol (CBD) is one of at least 113 phytocannabinoids produced by Cannabis sativa L. CBD is the most common cannabinoid in hemp plants, and the second most common cannabinoid, after THC, in some of the high-THC chemovars. The highest concentrations of CBD and other cannabinoids are found in the flowering tops of female cannabis plants. The cannabinoids produced as the plants grow and develop are primarily in acidic form. CBD is the non-acidic and is a homologue of cannabidiolic acid (CBDA).
In general, all the major cannabinoids present in cannabis and hemp first develop as “the mother of all cannabinoids,” cannabigerolic acid (CBGA). Plant enzymes unique to each cannabis strain convert the CBGA into some varying combination of the three major cannabinoid precursor compounds: tetrahydrocannabinolic acid (THCA), cannabichromenic acid (CBCA), cannabidiolic acid (CBDA). CBDA is then converted into CBD by thermal decarboxylation, whereby heat causes the molecule to lose its acidic carboxyl group. This decarboxylation process can either happen instantly, such as when the cannabis material is lit and smoked or vaporized, or by slow degradation over time if the plant material is left to sit at room temperature.
Since CBD is derived from cannabis, which is listed under Schedule I of the Controlled Substances Act (CSA), CBD products have not been widely available for purchase until recently. “For decades, federal law did not differentiate hemp from other cannabis plants, all of which were effectively made illegal in 1937 under the Marihuana Tax Act and formally made illegal in 1970 under the Controlled Substances Act – the latter banned cannabis of any kind.” Nonetheless, over the past several years, some producers have been offering CBD products alleged to be made from the mature stalks of cannabis plants, which are excluded from the definition of marijuana in the CSA. Such claims should be met with skepticism. “Cannabidiol expression is typically limited to flowering buds and not stalk fiber, or sterilized seeds; this is true of all cannabis varieties.” Additionally, this approach is of little legal value because any resin extracted from the stalk would be considered as a Schedule I substance – “an exception to the exemption.” Other producers took advantage of the industrial hemp pilot programs authorized under the Agricultural Act of 2014 (also known as the 2014 Farm Bill) to sell CBD products under the guise of market research.
Now, that the 2018 Farm Bill removed industrial hemp from the Controlled Substances Act and provided the legislative framework for the creation of a shared state-federal regulatory regime through which the U.S. Department of Agriculture (USDA) and/or states with USDA-approved regulatory plans may license hemp cultivators. While the cultivation of hemp will still be subject to very stringent guidelines and controls, the hemp CBD industry is expected to be worth billions of dollars within the next few years. This only means that CBD products will be available almost everywhere, and marketed as a variety of products including drugs, food, dietary supplements, cosmetics, and animal health products.
However, consumers must be very careful about purchasing any CBD product before consulting with a doctor.
Though cannabidiol comes from a plant, it is still a chemical that interacts with your mind and body. It can even make certain medications react differently. When putting anything in your body to better your health, it is always a good idea to have a healthcare professional involved.
Talking to a physician or a healthcare provider about using CBD oil can help you monitor the side effects, if any. While at home you can keep note of how you are feeling and how the medication is interacting with your body, doctors have the necessary resources that can help you monitor your progress. While CBD has been shown to be helping many people all over the world, it isn’t the perfect fit for everyone, and your doctor can help you come to that conclusion.
It is worth noting that there are many physicians and healthcare providers out there who acknowledge the therapeutic potential of CBD. The relationship you have with your doctor is one of the most important that you’ll ever have and taking the extra step to better understand a doctor’s decision-making style and his or her experience with your condition and CBD is a great way to begin building a trustworthy relationship.
Once you’ve located a local CBD-friendly doctor, go ahead and set up an introductory phone call or appointment. During the first visit, ask them about our Exclusive CBD products that are supplied to patients only after talking to a physician or a healthcare provider.
At FP Botanicals, we recognized that there is a plethora of CBD products in the market and the number of such products is only going to increase in the coming years, which has the potential to jeopardize the safety and efficacy of the products. Keeping the product safety and efficacy - in addition to rapidly changing FDA regulations - at the forefront of our mission, we developed cannabidiol (CBD) formulations that are supplied to consumers only after a discussion with their physician or healthcare provider ("PHP").
Unlike the current CBD manufacturers and sellers, whose products are sold everywhere; our products are made available only after consulting a physician or a healthcare provider about whether one needs to take CBD and if yes, which CBD formulation (i.e., tincture, capsule or a topical) best suits the needs of a patient.
 30. Aizpurua-Olaizola, et al. (2016, February 2). Evolution of the Cannabinoid and Terpene Content during the Growth of Cannabis sativa Plants from Different Chemotypes. Journal of Natural Products, 79(2), 324-331.  23. Russo, E.B., Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects.Br J Pharmacol, 2011. 163(7): p. 1344-64.  Hudak, J. (2018, December 14).The Farm Bill, hemp legalization and the status of CBD: An explainer. Retrieved from The Brookings Institution:https://www.brookings.edu/blog/fixgov/2018/12/14/the-farm-bill-hemp-and-cbdexplainer/  32. Drug Enforcement Agency. (2018, May 22). DEA Internal Directive Regarding the Presence of Cannabinoids in Products and Materials Made from the Cannabis Plant. Retrieved from Diversion Control Division: https://www.deadiversion.usdoj.gov/schedules/marijuana/dea_internal_directive_cannabinoids_05222018.html  33. Mead, A. (2017, May). The Legal Status of Cannabis (Marijuana) and Cannabidiol (CBD) Under U.S. Law. Epilepsy & Behavior, 70(Part B), 288-291.  Id.  Id.